Rallybio Corporation
RLYB
$0.298
-$0.0029-0.96%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 636.00K | 598.00K | 299.00K | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 636.00K | 598.00K | 299.00K | -- | -- |
| Cost of Revenue | 28.57M | 37.11M | 42.16M | 42.34M | 42.34M |
| Gross Profit | -27.94M | -36.51M | -41.86M | -42.34M | -42.34M |
| SG&A Expenses | 18.33M | 19.25M | 21.20M | 23.77M | 25.39M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 57.83M | 67.30M | 74.30M | 77.05M | 78.93M |
| Operating Income | -57.20M | -66.70M | -74.00M | -77.05M | -78.93M |
| Income Before Tax | -57.78M | -66.97M | -73.88M | -76.28M | -74.56M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -57.78 | -66.97 | -73.88 | -76.28 | -74.56 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -57.78M | -66.97M | -73.88M | -76.28M | -74.56M |
| EBIT | -57.20M | -66.70M | -74.00M | -77.05M | -78.93M |
| EBITDA | -57.07M | -66.56M | -73.86M | -76.90M | -78.78M |
| EPS Basic | -1.34 | -1.59 | -1.79 | -1.88 | -1.84 |
| Normalized Basic EPS | -0.79 | -0.94 | -1.07 | -1.12 | -1.15 |
| EPS Diluted | -1.34 | -1.59 | -1.79 | -1.88 | -1.84 |
| Normalized Diluted EPS | -0.79 | -0.94 | -1.07 | -1.12 | -1.15 |
| Average Basic Shares Outstanding | 174.16M | 170.13M | 166.07M | 162.31M | 161.78M |
| Average Diluted Shares Outstanding | 174.16M | 170.13M | 166.07M | 162.31M | 161.78M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |